Integrated Biopharma Stock

Integrated Biopharma P/B

The P/B (Price-to-Book Ratio) of Integrated Biopharma (INBP) as of Aug 7, 2026 is 0.46. In the previous year, P/B (Price-to-Book Ratio) was 0.48 — a change of -5.31% (lower).

P/B

0.46

YoY

-5.31%

Last updated:

P/B (Price-to-Book Ratio) of Integrated Biopharma is 2026 0.46 . P/B (Price-to-Book Ratio) of Integrated Biopharma was 2025 0.48 . It decreases by -5.31% lower compared to the previous year.
Access this data via the Eulerpool API

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrated Biopharma stock

P/B (Price-to-Book Ratio) of Integrated Biopharma is 0.46 in 2026.

P/B (Price-to-Book Ratio) of Integrated Biopharma changed from 0.48 to 0.46, representing a -5.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Integrated Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Integrated Biopharma

All Key Metrics — Integrated Biopharma